Source: https://www.pharmjournal.ru/jour/article/view/427
Timestamp: 2019-04-22 04:51:59+00:00

Document:
1. Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research / Institute of Medicine (US) Committee on Advancing Pain Research, Care, and Education. - Washington (DC): National Academies Press (US), 2011. 364 p.
2. Общие проблемы хронической и патологической боли. Курс образовательных статей по проблемам диагностики и лечения хронической боли. URL: https://www.painstudy.ru/education/index.php (дата обращения 11.02.2017).
3. H. Breivik, E. Eisenberg, T. O’Brien. The individual and societal burden of chronic pain in Europe: the case for strategic prioritisation and action to improve knowledge and availabilit y of appropriate care // BMC Public Health. 2013. V. 13. P. 1229-1243.
4. Болевой синдром. Клинические рекомендации. Общероссийская общественная организация «Ассоциация врачей общей практики (семейных врачей) Российской Федерации». - Москва - Санкт-Петербург - Ростов-на-Дону. 2014. 27 c.
5. С.С. Павленко. Состояние и проблемы эпидемиологических исследований болевых синдромов // Боль. 2006. № 4. C. 2-7.
6. А.Б. Данилов. Новые подходы в лечении пациентов с хронической болью// Лечащий врач. URL: http://www.lvrach. ru/2009/04/7634652/ (дата обращения 13.04.2017).
7. Steady Growth in Drug and Device Markets for Pain Management. Market Research Report // BCC Research LLC. 2015. № 8. Р. 28-36.
8. Pain Relieving Drugs Market Forecast 2017-2027. ReportBuyer Ltd. United Kingdom. Dec. 2016.
9. E. George, I. Elman. Pain in an era of armed conflicts: Prevention and treatment for warfighters and civilian casualties // Prog. Neurobiol. 2016. № 141. P. 25-44.
10. C. Giannou. M. Baldan. War Surgery. Working with limited resources in armed conflict and other situations of violence // International Committee of the Red Cross. 2010. V. 1. 283 р.
11. U. Friedman. Global Conflicts to Watch in 2017 / The Council on Foreign Relations (CFR). December 2016.
12. А.В. Соснов, С.С. Голубев, Б.С. Пункевич, С.В. Садовников, Ф.М. Семченко, В.Н. Тохмахчи, А.А. Соснова. Оценка потребности российской федерации в сильнодействующих анальгетиках // Разработка и регистрация лекарственных средств. 2016. № 2 (15). C. 202-215.
15. А.Д. Каприн. Фармакотерапия хронического болевого синдрома у взрослых пациентов при оказании паллиативной медицинской помощи в стационарных и амбулаторно-поликлинических условиях. Методические рекомендации / ФГБУ «ФМИЦ им. П.А. Герцена». - М.: Министерство здравоохранения РФ, 2015.
16. А.Д. Каприн, Р.Г. Абузарова. Фармакотерапия онкологической боли в России. Реальность и перспективы // Материалы Международного медицинского конгресса «Паллиативная медицина в здравоохранении Российской Федерации и стран СНГ». Москва. 2014. URL: www.palliamed.ru/files/ download/ file335.html (дата обращения 15.01.2017).
17. А.В. Соснов, С.В. Садовников, Ф.М. Семченко, К.А. Руфанов, В.Н. Тохмахчи, А.А. Соснова, И.А. Тюрин. Сильнодействующие ненаркотические анальгетики как направление развития фармацевтики // Разработка и регистрация лекарственных средств. 2016. № 1 (14). С. 196-207.
18. R. Sheu, D. Lussier, A. Rosenblum, et al. Prevalence and characteristics of chronic pain in patients admitted to an outpatient drug and alcohol treatment program // Pain Med. 2008. V. 9 (7). P. 911-917.
19. M. Egli, G.F. Koob, S. Edwards. Alcohol dependence as a chronic pain disorder // Neurosci. Biobehav. Rev. 2012. V. 36 (10). P. 2179-2192.
20. A.V. Apkarian, V. Neugebauer, G. Koob, et al. Neural mechanisms of pain and alcohol dependence // Pharmacol Biochem Behav. 2013 V. 112. P. 34-41.
21. J.L. Riley, C. King. Self-report of alcohol use for pain in a multi-ethnic community sample // J Pain. 2009. V. 10 (9). P. 944-952.
22. Horn-Hofmann et al. The effect of nonrecurring alcohol administration on pain perception in humans: a systematic review // Journal of Pain Research. 2015. V. 8. P. 175-187.
23. Повышение доступности наркотических и психотропных средств для использования в медицинских целях. Распоряжение Правительства РФ № 1403-р от 01.07.2016.
24. A.L. Harvey. Toxins and drug discovery. Review // Toxicon. 2014. V. 92. P. 193-200.
26. A. Caraceni at al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC // Lancet Oncol. 2012. V. 13 (2). P. 58-68.
27. P. Beaulieu, D. Lussier, F. Porreca, A. Dickenson. Pharmacology of Pain. - Seattle: IASP Press, 2010. 638 p.
28. A.S. Reddy, S. Zhang. Polypharmacology: drug discovery for the future // Expert Rev Clin Pharmacol. 2013 V. 6 (1). P. 43-47.
29. M. Duerden, T. Avery, R. Payne. Polypharmacy and medicines optimisation. - London. The King’s Fund. 2013. 56 р. URL: https:// www.kingsfund.org.uk /sites/files/kf/field/field_publication_file/ polypharmac y-and-medicines-optimisation-kingsfund-nov13. pdf (дата обращения 15.04.2017).
30. K. Barnett, S.W. Mercer, M. Norbury, G. Watt. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study // The Lancet. (2012). V. 380. P. 37-43.
31. C.E. Argoff, D.I. Silvershnein. A Comparison of Long- and Short-Acting Opioids for the Treatment of Chronic Noncancer Pain: Tailoring Therapy to Meet Patient Needs // Mayo Clin Proc. 2009. V. 84 (7). P. 602-612.
32. А.В. Соснов, С.С. Голубев, Б.С. Пункевич, С.В. Садовников, Е.М. Загребин, И.С. Родина, Ф.М. Семченко, А.А. Соснова. Стандартные образцы контролируемых сильнодействующих компонентов препаратов анальгетиков // Разработка и регистрация лекарственных средств. 2016. № 1 (14). C. 216-223.
34. P. Vergne-Salle. Лестница обезболивания ВОЗ: подходит ли она при боли в суставах? От НПВП к опиоидам // IASP. 2016. Fast sheet № 18.
35. М.Л. Кукушкин. Этиопатогенетические принципы лечения хронической боли // Лечащий Врач. 2008. № 4(8). URL: https://www.lvrach. ru/2008/04/5002175/ (дата обращения 15.04.2017).
37. Thomson Reuters Integrity. URL: http:// ip-science. thomsonreuters.com/ pharma/integrity_whatsnew/ (дата обращения 07.02.2017).
39. R.B. Raffa. Analgesic combinations // J Pain. 2010. V. 11(8). P 701-709.
41. (A) List of Narcotic analgesic combinations. URL: https://www.drugs.com/drug-class/narcotic-analgesic-combinations.html (дата обращения 07.02.2017). (B) Analgesics, Opioid Combos. URL: http://reference.medscape. com/drugs/analgesics-opioid-combos (дата обращения 07.02.2017).
42. A. Gatti, E. Sabato. Oxycodone/paracetamol: a low-dose synergic combination useful in different types of pain // Clin Drug Investig. 2010. V. 30 (2). P. 3-14.
43. J.V. Pergolizzi (Jr.), M. van de Laar, R. Langford, H.-U. Mellinghoff. Tramadol/paracetamol fixed-dose combination in the treatment of moderate to severe pain // Journal of Pain Research. 2012. V. 5. P. 327-346.
44. R.B. Raffa, J.V. Pergolizzi, D.J. Segarnick, R.J. Tallarida. Oxycodone combinations for pain relief // Drugs Today (Barc). 2010. V. 46(6). P. 379-398.
45. J. Moore et al. Dexketoprofen/tramadol: randomised double-blind trial and confirmation of empirical theory of combination analgesics in acute pain // The Journal of Headache and Pain. 2015. V. 16. P. 60.
46. P. Palmer. Compositions and methods for mild sedation, anxiolysis and analgesia in the procedural setting. EP2488156 A1. Acelrx Pharmaceuticals, Inc. 2012. URL: https://clinicaltrials.gov/ct2/show/ study/NCT00894699 (дата обращения 20.03.2017).
47. N. Zeynep, I. Akcaboy, Y. Erkan, I. Akcaboy, et al. Spinal anesthesia with lowdose bupivacaine-fentanyl combination: a good alternative for day case transurethral resection of prostate surgery in geriatric patients // Rev. Bras. Anestesiol. 2012. V. 62 (6). P. 753-761.
48. D.L. Cichewicz. Synergistic interactions between cannabinoid and opioid analgesics // Life Sci. 2004. V. 74(11). P. 1317-1324.
49. J. Elikkottil, P. Gupta, K. Gupta. The analgesic potential of cannabinoids // J Opioid Manag. 2009. V. 5(6). P. 341-357.
50. L.R. Gerak, C.P. France. Combined Treatment with Morphine and Δ9-Tetrahydrocannabinol in Rhesus Monkeys: Antinociceptive Tolerance and Withdrawal // Journal of Pharmacology and Experimental Therapeutics. 2016. V. 357 (2). P. 357-366.
51. D.R. Maguire, C.P. France. Interactions between cannabinoid receptor agonists and mu opioid receptor agonists in rhesus monkeys discriminating fentanyl // Eur J Pharmacol. 2016. V. 5 (784). P. 199-206.
52. Sebastiano Mercadante. Opioid combination: rationale and possible clinical applications // Ann Palliat Med. 2013. V 2(4). P. 189-196.
53. P.-P. Yang, G.-C. Yeh, E.Y.-K. Huang, P.-Y. Law, H.H. Loh, P.-L. Tao. Effects of dextromethorphan and oxycodone on treatment of neuropathic pain in mice // Journal of Biomedical Science. 2015. V. 22. P. 81.
54. C. Gharibo. Managing Chronic Moderate to Severe Pain-EMBEDA® (Morphine Sulfate and Naltrexone Hydrochloride) Extended Release Capsules for Oral Use // US Neurology. 2010. V. 6(1). P. 18-22.
55. L.R. Webster. Oxytrex: an oxycodone and ultra-low-dose naltrexone formulation // Expert Opin Investig Drugs. 2007. V. 16(8). P. 1277-83.
57. X. Wang, Y. Zhang, et al. Pharmacological characterization of the opioid inactive isomers (+)-naltrexone and (+)-naloxone as antagonists of toll-like receptor 4 // Br. J. Pharmacol. 2016. V. 173(5). P. 856.
58. V. Fernández-Dueñas, R. Poveda, et al. Fentanyl-trazodone-paracetamol triple drug combination: multimodal analgesia in a mouse model of visceral pain // Pharmacol Biochem Behav. 2011. V. 98(3). P. 331-336.
59. E. Schachtel, S. Daniels, et al. Results from using the nausea intensity scale: The severity of nausea is significantly reduced by CL-108 compared with a standard hydrocodone/acetaminophen analgesic when used to treat moderateto-severe pain // 16th World Congr Pain. Yokohama. September 26-30. 2016.
60. B. Schachte, et al. Clinically meaningful pain relief in patients with moderate to severe acute pain treated with CL-108 // 16th World Congr Pain. Yokohama. 2016.
61. K. Newman, J. Carsi, S. Han. Analgesic efficacy and safety of oxycodone 5 mg/ ibuprofen 400 mg compared with oxycodone 5 mg/acetaminophen 325 mg and hydrocodone 7,5 mg/acetaminophen 500 mg in the dental and orthopedic pain models // 25th Annu Sci Meet. Am Pain Soc. San Antonio. 2006.
62. J. Mao, M.S. Gold, M. Backonja. Combination Drug Therapy for Chronic Pain: A Call for More. Clinical Studies // J Pain. 2011. V. 12(2). P. 157-166.
63. A.A. Weinbroum at al. The role of dextromethorphan in pain control // Canadian Journal of Anaesthesia. 2000. V. 47(6). P.585-96.
64. Постановление Правительства РФ № 681 от 30 июня 1998 г. «Об утверждении перечня наркотических средств, психотропных веществ и их прекурсоров, подлежащих контролю в Российской Федерации» (с изменениями и дополнениями). URL: http://base.garant.ru/12112176/#ixzz4YBIlOJqX (дата обращения 15.03.2017).
65. V. Fernández-Dueñas, R. Poveda, S. Sánchez, F. Ciruela. Synergistic interaction between fentanyl and a tramadol: paracetamol combination on the inhibition of nociception in mice // J Pharmacol Sci. 2012. V. 118(2). P. 299-302.
66. R.B. Raffa, R.J. Tallarida, R Taylor. Fixeddose combinations for emerging treatment of pain // Expert Opin Pharmacother. 2012. V. 13(9). P. 1261-70.
67. N. Sambol, et al. Pharmacokinetics, safety, and tolerability of an NMDA-enhanced analgesic EN3231 in chronic pain patients who are slow and fast metabolizers of dextromethorphan // 10th World Congr Pain. San Diego. 2002. Abst 187-P183.
68. B.S. Galer, et al. MorphiDex(R) (morphine sulfate/dextromethorphan hydrobromide combination) in the treatment of chronic pain: Three multicenter, randomized, double-blind, controlled clinical trials fail to demonstrate enhanced opioid analgesia or reduction in tolerance // Pain. 2005. V. 115(3). P. 284.
69. Veterinary Anesthesia and Analgesia. 5th Ed. / Ed. by K.A. Grimm. - Wiley. 2015. 1072 p.
71. J.A.E. Hubbell at al. The use of sedatives, analgesic and anaesthetic drugs in the horse: An electronic survey of members of the American Association of Equine Practitioners (AAEP) // Equine Veterinary Journal. 2010. V. 42(6). P. 487-493.
72. J.A.E. Hubbell. Evaluation of midazolam-ketamine-xylazine infusion for total intravenous anesthesia in horses // American Journal of Veterinary Research. 2012. V. 73(4). P. 470-5.
73. A.K. Chan, C. W. Cheung, Y.K. Chong. Alpha-2 agonists in acute pain management // Expert Opin Pharmacother. 2010. V. 11(17). P. 2849-68.
74. J.A. Giovannitti, S.M. Thoms, J.J. Crawford. Alpha-2 Adrenergic Receptor Agonists: A Review of Current Clinical Applications // Anesth Prog. 2015. V. 62(1). P. 31-38.
75. D.D. Price, D.J. Mayer, J. Mao, F.S. Caruso. NMDA-receptor antagonists and opioid receptor interactions as related to analgesia and tolerance // J Pain Symptom Manage. 2000. V. 19(1). P. 7-11.
76. K. Subramaniam, B. Subramaniam, R. Steinbrook. Ketamine as adjuvant analgesic to opioids: a quantitative and qualitative systematic review // Anesth Analg. 2004. V. 99(2). P. 482-95.
77. D. Jamero, A. Borghol at al. The Emerging Role of NMDA Antagonists in Pain Management. U.S. Pharmacist. URL: http://www.medscape.com/viewarticle/744071_3 (дата обращения 02.02.2017).
78. C.S. Bonnet, A.S. Williams, et al. AMPA/kainate glutamate receptors contribute to inflammation, degeneration and pain related behaviour in inflammatory stages of arthritis // Ann Rheum Dis. 2015. V. 74(1). P. 242-51.
79. D.R. Kirkpatrick et al. Transmission pathways and mediators as the basis for clinical pharmacology of pain // Expert Rev Clin Pharmacol. 2016. V. 4. P. 1-25.
80. A Study to Evaluate the Clinical Efficacy, Safety and Tolerability of ARX-F03 Sublingual Sufentanil/Triazolam Nano-Tab™ in Patients Undergoing an Elective Abdominal Liposuction Procedure // ClinicalTrials. AcelRx Pharmaceuticals, Inc. URL: https://clinicaltrials.gov/show/NCT00894699 (дата обращения 02.02.2017).
81. D. Perret, Z.D. Luo. Targeting voltagegated calcium channels for neuropathic pain management // Neurotherapeutics. 2009. V. 6(4). P. 679-92.
82. S. Goyal et al. Comparison of the Effects of Zonisamide, Ethosuximide and Pregabalin in the Chronic Constriction Injury Induced Neuropathic Pain in Rats // Ann Med Health Sci Res. 2015. V. 5(3). P. 189-96.
83. J.A. Fidler, Y.A. Jamal, et al. GABA antagonist, delays return of righting reflex in mice after isoflurane anesthesia but does not significantly alter dendritic spine density. 46th Annu Meet Soc Neurosci. San Diego // 2016. Abst 343.20.
84. P. Compton, P. Kehoe, K. Sinha. Gabaрentin improves cold-pressor pain responses in methadone-maintained patients // Drug Alcohol Depend. 2010. V. 109(1-3). P. 213-9.
85. N. Stoicea, D. Russell, G. Weidner, M. Durda, Sergio D. Bergese. Opioidinduced hyperalgesia in chronic pain patients and the mitigating effects of gabapentin // Front Pharmacol. 2015. V. 27. P. 96-104.
86. D.R. Maguire, C.P. France. Impact of efficacy at the μ-opioid receptor on antinociceptive effects of combinations of μ-opioid receptor agonists and cannabinoid receptor agonists // J Pharmacol Exp Ther. 2014. V. 351(2). P. 383-9.
87. F. Shen, P.R. Tsuruda, J.A. Smith, G.P. Obedencio, W.J. Martin. Relative contributions of norepinephrine and serotonin transporters to antinociceptive synergy between monoamine reuptake inhibitors and morphine in the rat formalin model // PLoS One. 2013. V. 8(9). P. 74891.
88. M.L. Banks, K.C. Rice, S.S. Negus. Antinociceptive interactions between Mu-opioid receptor agonists and the serotonin uptake inhibitor clomipramine in rhesus monkeys: role of Mu agonist efficacy // J Pharmacol Exp Ther. 2010. V. 335(2). P. 497-505.
89. J.X. Li, W. Koek, K.C. Rice, C.P. France. Effects of direct- and indirect-acting serotonin receptor agonists on the antinociceptive and discriminative stimulus effects of morphine in rhesus monkeys // Neuropsychopharmacology. 2011. V. 36(5). P. 940-949.
90. Pain Management in Veterinary Practice / Editors: Christine M. Egger, Lydia Love, Tom Doherty. - NY: John Wiley & Sons, Ltd. 2014. 447 p.
91. D.L. Cichewicz, S.P. Welch, F.L. Smith. Enhancement of transdermal fentanyl and buprenorphine antinociception by transdermal delta9-tetrahydrocannabinol // Eur J Pharmacol. 2005. V. 525 (1-3). P. 74-82.
92. R.G. Pertwee. Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities // Philos Trans R Soc Lond B Biol Sci. 2012. V. 367(1607). P. 3353-3363.
93. I.A. Aljuffali, C.-F. Lin, C.-H. Chen & J.-Y. Fang. The codrug approach for facilitating drug delivery and bioactivity // Expert Opinion on Drug Delivery. 2016. V. 13 (9). P. 1311-1325.
94. H.K. Dhooper. Opioid-Cannabinoid Co-drugs with Enhanced Analgesic and Pharmacokinetic Profile: PhD dissertation. University of Kentucky. 2010. 160 p.
95. J.L. Wiley, M.M. O'connell, M.E. Tokarz, M.J. Wright. Pharmacological effects of acute and repeated administration of Delta(9)-tetrahydrocannabinol in adolescent and adult rats // J Pharmacol Exp Ther. 2007. V. 320 (3). P. 1097-1105.
97. R. Moorman-Li, C.A. Motycka, L.D. Inge, et al. A review of abuse-deterrent opioids for chronic nonmalignant pain // P&T®. 2012. V. 37(7). P. 412-418.
98. H. Soltani, A. Pardakhty. Marketed New Drug Delivery Systems for Opioid Agonists/Antagonists Administration: A Rapid Overview // Addict Health. 2016. V. 8(2). P. 115-122.
99. L.R. Webster, E.A. Kopecky, M.D. Smith, A.B. Fleming. A Randomized, Double-Blind, Double-Dummy Study to Evaluate the Intranasal Human Abuse Potential and Pharmacokinetics of a Novel Extended-Release Abuse-Deterrent Formulation of Oxycodone // Pain Med. 2016. V. 17(6). P. 1112-30.
100. M.E. Schatman, L.R. Webster. The health insurance industry: perpetuating the opioid crisis through policies of costcontainment and profitability // J Pain Res. 2015. V. 18(8). P. 153-158.
101. D.A. Tompkins, R.K. Lanier, J.A. Harrison, E.C. Strain, G.E. Bigelow. Human abuse liability assessment of oxycodone combined with ultra-low-dose naltrexone // Psychopharmacology (Berl). 2010. V. 210(4) P. 471-480.
102. L.R. Webster, J. Markman, E.J. Cone, G. Niebler. Current and future development of extended-release, abuse-deter- rent opioid formulations in the United States // Postgraduate Medicine. 2017. V. 129(1). P. 102-110.
103. S.G. Severtsona, M.S. Ellis, S.P. Kurtzc. Sustained reduction of diversion and abuse after introduction of an abuse deterrent formulation of extended release oxycodone // Drug and Alcohol Dependence. 2016. V. 168 P. 219-229.
104. S.D. Passik. Issues in long-term opioid therapy: unmet needs, risks, and solutions // Mayo Clin Proc. 2009. V. 84(7). P. 593-601.
105. I. Kissin. The Development of New Analgesics Over the Past 50 Years: A Lack of Real Breakthrough Drugs // Anesthesia and analgesia. 2010. V. 110(3). P. 780-789.
106. J.E. Barrett. Perspectives and Trends in Pharmacological Approaches to the Modulation of Pain // Adv Pharmacol. 2016. V. 75. P. 1-33.

References: V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V.